Centropomus undecimalis
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA472034 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR7219510_1.fastq.gz | Fastqsanger.gz | |||
| SRR7219510_2.fastq.gz | Fastqsanger.gz | |||
| SRR7219520_1.fastq.gz | Fastqsanger.gz | |||
| SRR7219520_2.fastq.gz | Fastqsanger.gz | |||
| SRR7219530_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 106 |
Similar Datasets
Project description:Effects of probiotics on common snook microbiota-Trial 1
| PRJNA472035 | ENA
Project description:Effects of probiotics on common snook microbiota-Trial 2
| PRJNA472048 | ENA
Project description:Effects of probiotics on common snook microbiota-Trial 2
| PRJNA472049 | ENA
Project description:Gemcitabine treatment shifts the intestinal microbiota of PC mice towards an inflammatory profile which may worsen mucositis and side effects observed upon chemotherapy. We explored the effect of a specific probiotics blend administered, with or without gemcitabine treatment, to PC xenografted mice.
2023-06-28 | E-MTAB-10676 | biostudies-arrayexpress
Project description:The pharmacological significance of B vitamins, essential for various metabolic processes, and the therapeutic potential of probiotics in gastrointestinal health have been well-documented. However, the interactions between these entities remain poorly understood. In this study, we endeavored to elucidate the potential interplay between B vitamins and probiotics utilizing liquid chromatography-triple quadrupole mass spectrometry, pharmacokinetic modeling, and 16S rRNA gene sequencing. Employing healthy and pseudo-germ-free rat models, we revealed that probiotics significantly improve the absorption of B1, B3, B5, and B12, and that the gut microbiota played a mediating role in this enhanced absorption of B vitamins by probiotics. High-throughput genetic sequencing uncovered a synergistic effect of B vitamins and probiotics in modulating the gut microbiota, particularly increasing the abundance of Verrucomicrobia and Akkermansia. Furthermore, in vitro experiments demonstrated that probiotics used in this study had a relatively minor influence on the production and permeability of B vitamins, while B vitamins did not significantly contribute to the growth, auto-aggregation, and adhesion of probiotics. In summary, a complex network connection exists between B vitamins and probiotics, wherein the gut microbiota emerges as a pivotal factor that cannot be overlooked.
2024-07-31 | GSE253146 | GEO
Project description:Asthma is multi-factorial disorder, and microbial dysbiosis enhances lung inflammation and asthma-related symptoms. Probiotics has shown anti-inflammatory effect and could regulate the gut-lung axis. Thus, a three-month randomized, double-blind, and placebo-controlled human trial was performed to investigate the adjunctive efficacy of probiotics in managing asthma.
2021-08-29 | MSV000088033 | MassIVE
Project description:Obesity and overweight are closely related to diet, and gut microbiota play an important role in body weight and human health. The aim of this study was to explore how Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 supplementation alleviate obesity by modulating the human gut microbiome. A randomized, double-blind, placebo-controlled study was conducted on 72 overweight individuals. Over a 12-week period, probiotic groups consumed 5×10^9 colony-forming units of HY7601 and KY1032), whereas the placebo group consumed the same product without probiotics. After treatment, the probiotic group displayed a reduction in body weight (p <0.001), visceral fat mass (p <0.025), and waist circumference (p <0.007), and an increase in adiponectin (p <0.046), compared with the placebo group. Additionally, HY7601 and KY1032 supplementation modulated bacterial gut microbiota characteristics and beta diversity by increasing Bifidobacteriaceae and Akkermansiaceae, and decreasing Prevotellaceae and Selenomonadaceae. In summary, HY7601 and KY1032 probiotics exert anti-obesity effects by regulating the gut microbiota; hence, they have therapeutic potential for preventing or alleviating obesity and overweight.
2022-05-12 | GSE202489 | GEO
Project description:Gut microbiota is an unignored target in maintaining intestinal homeostasis due to its regulatory effects on intestinal health through multiple mechanisms, including enhancing intestinal barriers, modulating microbial diversity, secreting various metabolites, etc. Bacteriocins produced by probiotics have been gradually proved vital for intestinal diseases intervention, however, the corresponding mechanisms have received less attention and the whole story of their regulative activities are hard to be fully uncovered. The two-peptide Plantaricin NC8 (PLNC8), coded by gene plnc8, is a bacteriocin ubiquitously produced by Lactobacillus plantarum, has been regarded as the potential vital bacteriocin for the anti-inflammatory effects of Lactobacillus plantarum. This study exploited CRISPR-cas9 and prokaryotic gene overexpression techniques to construct the plnc8 strains for the anti-inflammatory mechanism investigation. Based on the metagenomics, transcriptomics and metabolomics analysis, the anti-enteritis mechanism of PLNC8 systematically in DSS-induced enteritis models were comprehensively revealed. PLNC8 induced alterations in the composition of gut microbiota composition, promoting the alterations of multiple probiotics such as Eubacterium plexicaudatum, Doreasp.5-2, Enterococcus cecorum and Prevotella oulorum. Besides, various metabolites produced by the gut microbiota were influenced, and the key metabolites of xanthine, hypoxanthine, and L-histidine were regulated via purine and histidine metabolic pathways. These metabolites further inhibited p38 MAPK phosphorylation of enterocytes induced by DSS. Ultimately, the intestinal barrier repairment and anti- enteritis were achieved, proving the anti-enteritis effects of PLNC8 via microbe-metabolites-enterocyte axis.
2024-08-20 | GSE274981 | GEO
Project description:Probiotics have shown promise in positively altering gut microbiota and can potentially improve the gut flora of individuals with obesity. Recently, the development of probiotics with “Pharmabiotic” properties, which can reduce body fat and inhibit lipid accumulation, has emerged as a notable approach for effectively combating obesity. Nevertheless, owing to the lack of a universal methodology for elucidating the molecular mechanisms of probiotics, their antiobesity effects remain largely unknown. Herein, we developed an advanced multiomics-based strategy to decipher the mechanisms by which probiotics and their derivatives curtail adipocyte lipid production to affirm their antiobesity potential. Our initial investigation assessed the impact of probiotics and their derivatives on adipocyte differentiation and lipid generation at defined differentiation stages. Leveraging these insights, we performed comprehensive multiomics analyses at selected intervals to deepen our understanding regarding the suppression mechanisms of lipid formation. This framework confirmed the antiobesity efficacy of Lactobacillus reuteri lysate, targeting early differentiation to impede branched-chain amino acid (BCAA) catabolism and reduce adipocyte lipid accumulation. Specifically, L. reuteri lysate suppressed Krüppel-like factor 5 expression in early adipocyte differentiation phases, downregulating peroxisome proliferator–activated receptor gamma expression and reducing BCAA catabolism. Concurrently, L. reuteri lysate enhanced hypoxia-inducible factor 1 alpha expression, consequently downregulating lipin-1 expression in initial adipocyte differentiation stages, thus inhibiting adipogenesis. This study underscores the efficacy of our strategy in elucidating the intricate causal dynamics between host and microbiome, advancing therapeutic development and target exploration of probiotics.
2025-02-05 | PXD050884 | Pride